Immunotherapy for acute myeloid leukemia

被引：21

作者：

Jurcic J.G. ^{[1
]}

机构：

[1] Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021

来源：

Current Oncology Reports | 2005年 / 7卷 / 5期

关键词：

Acute Myeloid Leuke; Chronic Myeloid Leukemia; Hematopoietic Stem Cell Transplantation; Acute Promyelocytic Leukemia; Minimal Residual Disease;

D O I：

10.1007/s11912-005-0060-7

中图分类号：

学科分类号：

摘要：

Immunotherapeutic strategies have become part of standard cancer treatment. Chimeric and humanized antibodies have demonstrated activity against a variety of tumors. Although the humanized anti-CD33 antibody HuM195 has only modest activity against overt acute myeloid leukemia (AML), it can eliminate minimal residual disease in acute promyelocytic leukemia. High-dose radioimmunotherapy with β-particle-emitting isotopes targeting CD33, CD45, and CD66 can potentially allow intensification of antileukemic therapy before hematopoietic stem cell transplantation. Conversely, α-particle immunotherapy with isotopes such as bismuth-213 or actinium-225 offers the possibility of selective tumor cell kill while sparing surrounding normal tissues. Targeted chemotherapy with the anti-CD33-calicheamicin construct gemtuzumab ozogamicin has produced remissions in relapsed AML and appears promising when used in combination with standard chemotherapy for newly diagnosed AML. T-cell recognition of peptide antigens presented on the cell surface in combination with major histocompatibility complex antigen provides another potentially promising approach for the treatment of AML. Copyright © 2005 by Current Science Inc.

引用

页码：339 / 346

页数：7

共 51 条

[1]

Diaconescu R., Storb R., Allogeneic hematopoietic cell transplantation: From experimental biology to clinical care, J. Cancer Res. Clin. Oncol., 131, pp. 1-13, (2005)

[2]

Ho V.T., Alyea E.P., Donor lymphocyte infusions, Treatment of Leukemia and Lymphoma, pp. 319-345, (2004)

[3]

Andrews R.G., Takahashi M., Segal G.M., Et al., The L4F3 antigen is expressed by unipotent colony-forming cells but not by their precursors, Blood, 68, pp. 1030-1035, (1986)

[4]

Scheinberg D.A., Lovett D., Divgi C.R., Et al., A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: Specific bone marrow targeting and internalization of radionuclide, J. Clin. Oncol., 9, pp. 478-490, (1991)

[5]

Caron P.C., Co M.S., Bull M.K., Et al., Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies, Cancer Res., 52, pp. 6761-6767, (1992)

[6]

Caron P.C., Jurcic J.G., Scott A.M., Et al., A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: Specific targeting without immunogenicity, Blood, 83, pp. 1760-1768, (1994)

[7]

Xu Y., Scheinberg D.A., Elimination of human leukemia by monoclonal antibodies in an athymic nude mouse leukemia model, Clin. Cancer Res., 1, pp. 1179-1187, (1995)

[8]

Caron P.C., Dumont L., Scheinberg D.A., Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia, Clin. Cancer Res., 4, pp. 1421-1428, (1998)

[9]

Feldman E., Kalaycio M., Weiner G., Et al., Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195, Leukemia, 17, pp. 314-318, (2003)

[10]

Feldman E., Stone R.M., Brandwein J., Et al., Phase III randomized trial of an anti-CD33 monoclonal antibody (HuM195) in combination with chemotherapy compared to chemotherapy alone in adults with refractory or first-relapse acute myeloid leukemia (AML), Proc. ASCO, 21, (2002)

← 1 2 3 4 5 6 →